LOS ANGELES, Sept. 2 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced earlier today that breaking news will be issued tomorrow, at the opening of the market, regarding the law firm of Vianale & Vianale, and others.
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.
Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are
"forward- looking" statements. Forward-looking statements involve known and
unknown risks, which may cause the companies' actual results in the future
to differ materially from expected results. Factors which could cause or
contribute to such differences include, but are not limited to, failure to
complete the development and introduction of heart monitoring and other
biomedical devices incorporating the companies' technology procure market
acceptance for these products, failure to obtain federal or state or
governmental or international regulatory approvals governing heart
monitoring and other biomedical devices incorporating the technology,
failure to obtain import and export capabilities in the various countries
containing buyers and resellers and hospitals and clinics and doctors for
the devices, inability to obtain physician, patient or insurance acceptance
of or for heart monitoring and other biomedical incorporating of the
technologies, and the unavailability of financing to complete management's
plans and objectives, including th
|SOURCE Signalife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved